Search results
Showing 211 to 225 of 435 results for cardiovascular disease
Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up.
monitoring treatment and blood pressure targets for people without cardiovascular disease. Full details of the evidence and the...
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
the rationale and impact section on blood pressure targets for people with cardiovascular disease. Full details of the evidence and the...
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid modification
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
diabetes. Source guidance details Comes from guidance Cardiovascular disease: risk assessment and reduction, including lipid...
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Alitretinoin for the treatment of severe chronic hand eczema (TA177)
Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.
prevention of CVD and should be recommended for those at 10% risk of cardiovascular events as assessed using the QRISK2 calculator....
Intrabeam radiotherapy for treating early breast cancer Cardiovascular conditions (heart disease and stroke) How do I...
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.